Trends in Hepatitis B Virus Resistance to Nucleoside/Nucleotide Analogs in North China from 2009 to 2016: A Retrospective Study

Globally, an estimated 240 million people are chronically infected with hepatitis B virus (HBV) [1], and they are at an increased risk of developing cirrhosis and hepatocellular carcinoma (HCC) [2]. HBV infection is endemic in China, where more than 120 million people carry hepatitis B surface antigen (HBsAg), and approximately 300,000 of them die annually of liver cirrhosis or HCC [3]. Both interferon (IFN) and nucleos(t)ide analogs (NAs) are currently used to treat HBV infection [4]. NAs are more widely used due to having fewer adverse effects than IFN [4].

Source: International Journal of Antimicrobial Agents - April 11, 2018 Category: Drugs & Pharmacology Authors: Xianghua Guo, Jushan Wu, Feili Wei, Yabo Ouyang, Qing Li, Kai Liu, Yanjun Wang, Yulin Zhang, Dexi Chen Source Type: research